Aktuelle investeringer
1852 Investeringer
Titel Sortér faldende | Periode | Program | |
---|---|---|---|
ACD-plugin – a disinfective easy-to-install solution for improvement of air quality in cars | 2019 - 2020 | Innobooster
|
|
ACD-plugin – a disinfective easy-to-install solution for improvement of air quality in cars
Periode
2019 - 2020
Region
Program
Innobooster Fagområde
Biotek, Medico og Sundhed Investering
Percentage
33 Fondens investering
490.050 Samlet budget
1,5 mio. Lugtgener fra bilens ventilationsanlæg pga. akkumulering af bakterier og svamp er et velkendt problem, som kan have konsekvenser for sundhed og indeklima. ACD ApS har udviklet en innovativ løsning, ACD-Plugin, som er et lille UVC LED-lys i form af et plugin, tilpasset snævre og sværttilgængelige ventilationssystemer, som det der findes i biler. Den desinficerende effekt af UVC forstærkes af en antibakteriel TiO2-behandling, som med påvist effekt udraderer akkumulerede patogene.
Projektdeltagere
ACD ApS Projektleder
Aktiv
Læs mere om projektet
| |||
ACOUPLAST | 2019 - 2022 | Internationalt samarbejde
|
|
ACOUPLAST
Periode
2019 - 2022
Region
Program
Internationalt samarbejde Fagområde
Biotek, Medico og Sundhed Investering
Percentage
24.2 Fondens investering
2,8 mio. Samlet budget
11,5 mio. ACOUPLAST aims to reach a 900M€/year market opportunity with the development of a polymer acoustofluidic chip for high-performing, fast and cost-effective plasma separation, to enable healthcare and veterinary Point-of-Care (PoC) diagnostics. Targeting life science companies, we will deliver AcouPlast chip modules for integration in single-use test cartridges. The solution is a recent research breakthrough by DTU Physics, experimentally validated by ACS, resulting in a patent application.
Projektdeltagere
DTU, Ortofon A/S, AcouSort AB, Lund University Projektleder
Aktiv
Læs mere om projektet
| |||
Acromegaly | 2018 - 2021 | Erhvervsforsker
|
|
Acromegaly
Periode
2018 - 2021
Region
Program
Erhvervsforsker Fagområde
Biotek, Medico og Sundhed Investering
Percentage
42.3 Fondens investering
1,1 mio. Samlet budget
2,5 mio. Akromegali er en sjælden sygdom forårsaget af øget niveauer af væksthormon, hvilket ofte er forårsaget af en godartet tumor i hypofysen. Flere studier peger på, at GIP receptoren (GIPR) kan forårsage de øgede væksthormonniveauer i en del af patienterne med akromegali. Vi er i den unikke situation, at vi har en GIPR antagonist, som kan bruges i mennesker. Med den vil vi klarlægge GIPRs involvering i akromegali og validere om GIPR antagonister kan bruges terapeutisk i denne patientgruppe.
Projektdeltagere
Københavns Universitet, Antag Therapeutics ApS Projektleder
Aktiv
Læs mere om projektet
| |||
Activation of Kv3 channels as a novel and innovative approach to treat schizophrenia | 2016 - 2019 | Erhvervsforsker
|
|
Activation of Kv3 channels as a novel and innovative approach to treat schizophrenia
Periode
2016 - 2019
Region
Program
Erhvervsforsker Fagområde
Biotek, Medico og Sundhed Investering
Percentage
40.57 Fondens investering
1,1 mio. Samlet budget
2,7 mio. We aim at developing a novel an innovative treatment opportunity for schizophrenia. Schizophrenia encompasses three different disease domains recognized as positive, negative and cognitive symptoms. Current medication is inadequate against negative and cognitive symptoms. By pursuing a novel target that has demonstrated promising preclinical result we aim at developing a new treatment paradigm for untreated symptoms in schizophrenia thereby covering a high unmet need.
Projektdeltagere
H LUNDBECK A/S Københavns Universitet Projektleder
Aktiv
Læs mere om projektet
| |||
ActiveCube - Active Substrate for Point-of-Load Power Converters | 2019 - 2020 | Innoexplorer
|
|
ActiveCube - Active Substrate for Point-of-Load Power Converters
Periode
2019 - 2020
Region
Program
Innoexplorer Fagområde
Produktion, Materialer, Digitalisering og IKT Investering
Percentage
100 Fondens investering
1,5 mio. Samlet budget
1,5 mio. Projektdeltagere
Danmarks Tekniske Universitet (DTU ELEKTRO) Projektleder
Aktiv
Læs mere om projektet
| |||
ActiVITAE | 2018 - 2019 | Internationalt samarbejde
|
|
ActiVITAE
Periode
2018 - 2019
Region
Program
Internationalt samarbejde Fagområde
Produktion, Materialer, Digitalisering og IKT Investering
Percentage
11.56 Fondens investering
329.026 Samlet budget
2,8 mio. Chronic pain affects more than 1.5 billion individuals globally – and is the single most prevalent symptom among geriatric patients. Chronic pain has tremendous impact on individuals’ wellbeing, lifestyle, independence, activity and comfort, and the condition is associated with the spiral degeneration of general quality of life of older adults, with increased disability, deconditioning and hence, increased change on frailty.
ActiVITAE aims to help people ageing well by alleviating geriatric chronic pain using our completely novel and patented, ICT-based pain management system. The solution, Vibration Induced Treatment by Abdominal Excitation (VITAE), is disruptive and provides a pleasant, non-invasive Vagal Nerve Stimulation (VNS), utilising abdominal vibro-tactile stimulation of the Pacinian corpuscles.
Projektdeltagere
mediathand ApS, University Medical Center Groningen, Ospedale Polclinco San Martino Projektleder
Aktiv
Læs mere om projektet
| |||
AD Shield | 2019 - 2021 | Internationalt samarbejde
|
|
AD Shield
Periode
2019 - 2021
Region
Program
Internationalt samarbejde Fagområde
Produktion, Materialer, Digitalisering og IKT Investering
Percentage
26.97 Fondens investering
2,8 mio. Samlet budget
10,3 mio. The project goal is to bring to the clinical market and mass market an easily accessible, user-friendly and
motivating digital medical device called (Alzheimer’s disease) AD Shield, delivered on tablets, smartphones and PCs/Mac.
The main result will offer presymptomatic detection of AD and personalized AD prevention programs in the form of gamified cognitive training and behavioural interventions in one seamless product.
The product targets citizens with the highest risk of AD (due to an acute unmet clinical need) and the healthcare professionals that serve these segments.
OVERALL AMBITION: The goal is to create and become the global standard for presymptomatic AD care.
Projektdeltagere
AU, AUH, Brain+ ApS, Lytics Health AB, Research Institutes of Sweden, Interactive Institute AB Projektleder
Aktiv
Læs mere om projektet
| |||
Adaptive and self-learning slaughterhouse robots | 2017 - 2019 | Erhvervsforsker
|
|
Adaptive and self-learning slaughterhouse robots
Periode
2017 - 2019
Region
Program
Erhvervsforsker Fagområde
Produktion, Materialer, Digitalisering og IKT Investering
Percentage
54.44 Fondens investering
1,1 mio. Samlet budget
2,0 mio. The project is concerned with research in adaptive learning algorithms, which will enable robots to react to variations in input, continuously perform corrections during operations and make adjustments to subsequent operations using feedback from the evaluation of the produced output. Additionally, the individual work process will make use of information collected along the production line in order to optimize its operation.
Projektdeltagere
Teknologisk Institut Aalborg Universitet Projektleder
Aktiv
Læs mere om projektet
| |||
Adaptive Xray InSpection | 2018 - 2022 | Grand Solutions
|
|
Adaptive Xray InSpection
Periode
2018 - 2022
Region
Program
Grand Solutions Fagområde
Produktion, Materialer, Digitalisering og IKT Investering
Percentage
54.33 Fondens investering
9,1 mio. Samlet budget
16,8 mio. What is the innovation and the need behind the innovation?:
AXIS will apply SotA artificial intelligence to automate the implementation of x-ray inspection systems. AXIS will automate classification software and the hardware specifications.;
What is the most important competing solution?:
No true competitors exist, a number of domain-specific competitors exist. We know of nobody that use AI for x-ray inspection.;
Who will ultimately receive the value created?:
Newtec, Qtechnology, and Magnatec all have business plans for the project results. ;
What will the applied investment from Innovation Fund Denmark mainly be used for?:
Research into a fully automated, x-ray based classification system, including x-ray equipment that works with the AI system.;
How will the project results be implemented?
Qtechnology and Magnatec will market components and Newtec will market full systems.
Projektdeltagere
University of Copenhagen (Niels Bohr Instituet), Qtechnology A/S, Magnatek Aps, Newtec, Teknologisk Institut Projektleder
Aktiv
Læs mere om projektet
| |||
Adaptivt Lys i Transparente Rum | 2017 - 2021 | Erhvervsforsker
|
|
Adaptivt Lys i Transparente Rum
Periode
2017 - 2021
Region
Program
Erhvervsforsker Fagområde
Infrastruktur, Transport og Byggeri Investering
Percentage
111.57 Fondens investering
964.000 Samlet budget
864.000 Projektet skaber ny viden om hvordan brugen af kompositte transparente materialer i en tæt urban kontekst bringer særlige lyskvaliteter ind i gade- og indendørs rum, og gestalter nogle nye forhold mellem inde og ude, mellem mennesker, naboer og bymiljø, og mellem kunst- og dagslys. Med IoT infrastruktur og software services opnår byens arkitektur nye indbyggede potentialer for adaptive funktioner, hvor kombinerede egenskaber af lyshed, skygge og transparens kan dynamisk tilpasses behov.
Projektdeltagere
KHR Architecture AS Det Kongelige Danske Kunstakademis Skoler for Arkitektur, Design og Konservering Projektleder
Aktiv
Læs mere om projektet
| |||
ADCendo ApS - A biotech spinout developing novel anti-cancer drugs in the form of antibody drug conjugates (ADCs) | 2019 - 2020 | Innobooster
|
|
ADCendo ApS - A biotech spinout developing novel anti-cancer drugs in the form of antibody drug conjugates (ADCs)
Periode
2019 - 2020
Region
Program
Innobooster Fagområde
Biotek, Medico og Sundhed Investering
Percentage
30 Fondens investering
483.600 Samlet budget
1,6 mio. ADCendo ApS is a biotech spin-out established in 2017, with a vision to develop new anti-cancer drugs directed at a novel target, in the form of antibody-drug conjugates (ADCs). Current activities revolve around optimization of ADCendos first drug candidate, involving collaboration with international pharma companies. Thereby, this InnoBooster project will enable identification of a lead candidate, and contribute with key progress involving international knowledge- and technology providers.
Projektdeltagere
ADCendo ApS Projektleder
Aktiv
Læs mere om projektet
| |||
ADCendo ApS - first-in-class targeted cancer drugs | 2019 - 2020 | Innofounder
|
|
ADCendo ApS - first-in-class targeted cancer drugs
Periode
2019 - 2020
Region
Program
Innofounder Fagområde
Biotek, Medico og Sundhed Investering
Percentage
100 Fondens investering
460.000 Samlet budget
460.000 In 40 years, only one drug, recently failed, has been approved for first-line therapy of sarcoma cancer. Through targeted therapy exploiting a novel antigen, ADCendo seeks to address this unmet need.
Projektdeltagere
Christoffer Fagernæs Nielsen Projektleder
Aktiv
Læs mere om projektet
| |||
Adherence through cloud-based Personalised Treatment for Type 2 Diabetes ADAPT-T2D ADAPT-T2D | 2019 - 2024 | Grand Solutions
|
|
Adherence through cloud-based Personalised Treatment for Type 2 Diabetes ADAPT-T2D ADAPT-T2D
Periode
2019 - 2024
Region
Program
Grand Solutions Fagområde
Biotek, Medico og Sundhed Investering
Percentage
52.12 Fondens investering
17,1 mio. Samlet budget
32,9 mio. We propose cloud-based, personalised treatment to improve real-world adherence and outcomes for type 2 diabetes (T2D) patients. Adherence inhibits most T2D patients from reaching treatment targets. This impacts health, quality of life and cost society. To support care teams and empower patients to self-manage, we integrate data from continuous glucose monitors, connected insulin pens and activity trackers and provide real-time, personalised treatment guidance, data-derived insights, hypoglycemia warnings and dose reminders. Methods include large-scale data collection, development of a high-fidelity T2D model and required algorithms, and clinical feasibility testing of the full solution.
Projektdeltagere
Region Sjælland, Novo Nordisk A/S, Aalborg University (Department of Electronic Systems), Technical University of Denmark (DTU Compute, Scientific computing), University of Cambridge (Department of Paediatrics), Glooko AB, Aalborg Universitetshospital (Region Nordjylland) Projektleder
Aktiv
Læs mere om projektet
| |||
Adipose tissue function, insulin receptors and adipogenesis | 2017 - 2020 | Erhvervsforsker
|
|
Adipose tissue function, insulin receptors and adipogenesis
Periode
2017 - 2020
Region
Program
Erhvervsforsker Fagområde
Biotek, Medico og Sundhed Investering
Percentage
64.58 Fondens investering
1,1 mio. Samlet budget
1,7 mio. Insulin action in adipose tissue is central to metabolic control. Increases in fat mass can be driven by expansion of existing adipocytes or by recruitment of new adipocytes (adipogenesis). Preadipocytes are highly sensitive to insulin and IGF-1 in the differentiation process. This study will clarify the roles of InsR and IGF-1R in adipogenesis and provide important insights into the role of insulin in adipose tissue function, expansion and insulin sensitivity.
Projektdeltagere
Novo Nordisk A/S Syddansk Universitet Projektleder
Aktiv
Læs mere om projektet
| |||
ADORNO AR - Bridging the gap between the physical and the digital world | 2019 - 2019 | Innobooster
|
|
ADORNO AR - Bridging the gap between the physical and the digital world
Periode
2019 - 2019
Region
Program
Innobooster Fagområde
Produktion, Materialer, Digitalisering og IKT Investering
Percentage
33 Fondens investering
256.409 Samlet budget
777.000 Med Adorno AR vil Adorno Digital tilbyde et produkt, hvormed designere,
kunstenere, gallerier og deslignende kan få skabt 3D-modeller af deres værker,
hvilket vil øge deres chancer for at sælge værkerne online signifikant. Dette
påvises af 2 markedsundersøgelser udarbejdet af Adorno Digital. Adorno AR er
et disruptivt produkt idet produktionen er betydeligt mere automatiseret,
hvilket gør at produktionen af en 3D-model med Adorno AR er meget billigere
og hurtigere, and andre på markedet.
Projektdeltagere
Adorno Digital IVS Projektleder
Aktiv
Læs mere om projektet
|